CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.

Handel Annexon, Inc. - ANNX CFD

3.20
2.89%
0.06
Lav: 2.98
Høj: 3.2
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.06
Long position, gebyr natten over

Long position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.025457%
Short position, gebyr natten over

Short position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
0.003235%
Gebyr natten over, tid 21:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Annexon Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

Nøglestatistikker
Tidligere luk* 3.11
Åben* 3.15
1-Års Ændring* -6.25%
Dagens Spænd* 2.98 - 3.2
52-Ugers Spænd 2.07-7.65
Gennemsnitlig Volumen (10 dage) 2.55M
Gennemsnitlig Volumen (3 måneder) 16.64M
Market Cap 158.19M
P/E-forhold -100.00K
Udestående aktier 53.08M
Omsætning N/A
EPS -2.47
Dividend (Udbytte %) N/A
Beta -100.00K
Næste indtjeningsopgørelse Aug 7, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Jun 6, 2023 3.20 0.14 4.58% 3.06 3.22 2.98
Jun 5, 2023 3.11 0.15 5.07% 2.96 3.23 2.87
Jun 1, 2023 3.14 0.22 7.53% 2.92 3.20 2.81
May 31, 2023 2.97 0.14 4.95% 2.83 3.03 2.60
May 30, 2023 2.71 0.02 0.74% 2.69 2.95 2.48
May 26, 2023 2.78 0.71 34.30% 2.07 2.81 2.05
May 25, 2023 2.06 -0.36 -14.88% 2.42 2.44 2.04
May 24, 2023 5.15 -0.33 -6.02% 5.48 5.63 5.05
May 23, 2023 5.57 -0.22 -3.80% 5.79 6.09 5.56
May 22, 2023 5.94 0.27 4.76% 5.67 6.04 5.66
May 19, 2023 5.86 0.13 2.27% 5.73 5.97 5.67
May 18, 2023 5.76 -0.47 -7.54% 6.23 6.61 5.72
May 17, 2023 6.35 0.38 6.37% 5.97 6.40 5.78
May 16, 2023 6.00 0.06 1.01% 5.94 6.15 5.77
May 15, 2023 6.03 0.60 11.05% 5.43 6.22 5.41
May 12, 2023 5.44 -0.02 -0.37% 5.46 5.59 5.41
May 11, 2023 5.45 -0.15 -2.68% 5.60 5.67 5.38
May 10, 2023 5.59 0.20 3.71% 5.39 5.79 5.35
May 9, 2023 5.43 0.33 6.47% 5.10 5.48 4.90
May 8, 2023 5.21 0.17 3.37% 5.04 5.26 5.03

Annexon, Inc. Events

Tid (UTC) (UTC) Land Begivenhed
Thursday, June 8, 2023

Tid (UTC) (UTC)

13:30

Land

US

Begivenhed

Annexon Inc Annual Shareholders Meeting
Annexon Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, June 9, 2023

Tid (UTC) (UTC)

16:00

Land

US

Begivenhed

Annexon Inc Annual Shareholders Meeting
Annexon Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 7, 2023

Tid (UTC) (UTC)

10:59

Land

US

Begivenhed

Q2 2023 Annexon Inc Earnings Release
Q2 2023 Annexon Inc Earnings Release

Forecast

-

Previous

-
Wednesday, November 1, 2023

Tid (UTC) (UTC)

12:30

Land

US

Begivenhed

Q3 2023 Annexon Inc Earnings Release
Q3 2023 Annexon Inc Earnings Release

Forecast

-

Previous

-
Se alle begivenheder
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Total omsætning 0 0 0 0 0
Totale Driftsudgifter 145.599 130.713 63.469 32.328 19.112
Salgs/Generelle/Admin. Udgifter, Total 33.098 30.647 14.198 7.994 3.619
Forskning & Udvikling 112.501 100.066 49.271 24.524 15.528
Driftsindtægter -145.599 -130.713 -63.469 -32.328 -19.112
Andre, Netto 3.652 0.385 0.048 -4.865 0.769
Netto Indkomst Før Skat -141.947 -130.323 -63.412 -37.179 -18.303
Netto Indkomst Efter Skat -141.947 -130.323 -63.412 -37.183 -18.304
Netto Indkomst Før Ekstra Ting -141.947 -130.323 -63.412 -37.183 -18.304
Totale Ekstraordinære Ting
Netto Indkomst -141.947 -130.323 -63.412 -37.183 -18.304
Total Adjustments to Net Income 0 -6.924 -1.095 -0.176
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -141.947 -130.323 -70.336 -38.278 -18.48
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -141.947 -130.323 -70.336 -38.278 -18.48
Fortyndet Netto Indkomst -141.947 -130.323 -70.336 -38.278 -18.48
Fortyndet Vægtet Gennemsnit Aktier 54.6736 38.3163 16.9624 187.289 187.289
Fortyndet EPS Uden Ekstraordinære Ting -2.59626 -3.40124 -4.14658 -0.20438 -0.09867
Dividends per Share - Common Stock Primary Issue 0 0
Fortyndet Normaliseret EPS -2.59626 -3.40124 -4.14658 -0.20504 -0.09879
Usædvanlig Udgift (Indkomst) -0.19 -0.035
Renteindkomst (Udgift), Netto Ikke-Drift 0.005 0.009 0.014 0.04
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total omsætning 0 0 0 0 0
Totale Driftsudgifter 41.242 36.695 36.069 37.409 35.426
Salgs/Generelle/Admin. Udgifter, Total 8.897 8.16 8.207 8.303 8.428
Forskning & Udvikling 32.345 28.535 27.862 29.106 26.998
Driftsindtægter -41.242 -36.695 -36.069 -37.409 -35.426
Andre, Netto 2.566 2.312 1.015 0.272 0.053
Netto Indkomst Før Skat -38.676 -34.383 -35.054 -37.137 -35.373
Netto Indkomst Efter Skat -38.676 -34.383 -35.054 -37.137 -35.373
Netto Indkomst Før Ekstra Ting -38.676 -34.383 -35.054 -37.137 -35.373
Netto Indkomst -38.676 -34.383 -35.054 -37.137 -35.373
Total Adjustments to Net Income
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -38.676 -34.383 -35.054 -37.137 -35.373
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -38.676 -34.383 -35.054 -37.137 -35.373
Fortyndet Netto Indkomst -38.676 -34.383 -35.054 -37.137 -35.373
Fortyndet Vægtet Gennemsnit Aktier 73.8556 72.563 68.6529 38.5844 38.5634
Fortyndet EPS Uden Ekstraordinære Ting -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.52367 -0.47384 -0.5106 -0.96249 -0.91727
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Totale Nuværende Aktiver 248.098 247.693 354.011 45.406 45.706
Likvider og Kortsigtede Investeringer 242.657 242.715 351.206 43.931 44.175
Likvider & Lignende 140.02 74.843 268.565 43.931 44.175
Prepaid Expenses 5.238 4.515 2.802 1.396 1.306
Total Assets 285.096 287.04 355.946 49.898 48.149
Property/Plant/Equipment, Total - Net 35.966 38.181 1.935 2.138 2.345
Property/Plant/Equipment, Total - Gross 38.849 38.97 3.906 3.442 3.156
Accumulated Depreciation, Total -2.883 -0.789 -1.971 -1.304 -0.811
Other Long Term Assets, Total 1.032 1.166 0 2.354 0.098
Total Current Liabilities 22.36 21.744 10.622 4.931 3.326
Accounts Payable 7.416 11.153 3.734 2.371 1.271
Accrued Expenses 14.764 10.452 6.497 2.194 1.713
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.18 0.139 0.391 0.366 0.342
Total Liabilities 53.902 55.131 11.668 6.368 5.129
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 31.542 33.387 1.046 1.437 1.803
Total Equity 231.194 231.909 344.278 43.53 43.02
Redeemable Preferred Stock 0 0 143.984 107.222
Common Stock 0.048 0.039 0.038 0.004 0.004
Additional Paid-In Capital 669.78 528.365 510.309 2.202 1.257
Retained Earnings (Accumulated Deficit) -438.262 -296.315 -165.992 -102.58 -65.397
Other Equity, Total -0.372 -0.18 -0.077 -0.08 -0.066
Total Liabilities & Shareholders’ Equity 285.096 287.04 355.946 49.898 48.149
Total Common Shares Outstanding 47.723 38.5608 38.1576 187.289 187.289
Totale Tilgodehavender, Netto 0 0.003 0.079 0.225
Kortsigtede Investeringer 102.637 167.872 82.641
Other Current Assets, Total 0.203 0.463
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Totale Nuværende Aktiver 232.536 248.098 274.777 181.372 211.254
Likvider og Kortsigtede Investeringer 228.165 242.657 269.519 177.594 206.659
Likvider & Lignende 144.12 140.02 210.658 104.614 112.828
Kortsigtede Investeringer 84.045 102.637 58.861 72.98 93.831
Totale Tilgodehavender, Netto
Prepaid Expenses 4.206 5.238 5.201 3.741 4.461
Total Assets 268.778 285.096 312.722 220.704 250.569
Property/Plant/Equipment, Total - Net 35.198 35.966 36.709 37.282 37.908
Accumulated Depreciation, Total -3.419 -2.883 -2.353 -1.834 -1.295
Other Long Term Assets, Total 1.044 1.032 1.236 2.05 1.407
Total Current Liabilities 22.941 22.36 20.22 20.254 17.053
Accounts Payable 10.346 7.416 6.921 10.301 9.378
Accrued Expenses 12.211 14.764 13.129 9.789 7.486
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.384 0.18 0.17 0.164 0.189
Total Liabilities 53.917 53.902 52.12 52.66 49.955
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 30.976 31.542 31.9 32.406 32.902
Total Equity 214.861 231.194 260.602 168.044 200.614
Common Stock 0.053 0.048 0.048 0.039 0.039
Additional Paid-In Capital 691.963 669.78 664.839 537.269 532.636
Retained Earnings (Accumulated Deficit) -476.938 -438.262 -403.879 -368.825 -331.688
Other Equity, Total -0.217 -0.372 -0.406 -0.439 -0.373
Total Liabilities & Shareholders’ Equity 268.778 285.096 312.722 220.704 250.569
Total Common Shares Outstanding 53.0807 47.723 47.6265 38.6039 38.5636
Property/Plant/Equipment, Total - Gross 38.617 38.849 39.062 39.116 39.203
Other Current Assets, Total 0.165 0.203 0.057 0.037 0.134
Redeemable Preferred Stock
  • Årlig
  • Pr kvartal
2022 2021 2020 2019 2018
Netto indkomst/Startlinje -141.947 -130.323 -63.412 -37.183 -18.304
Likvider Fra Driftsaktiviteter -116.309 -106.11 -53.087 -28.358 -17.19
Likvider Fra Driftsaktiviteter 2.106 2.141 0.667 0.493 0.488
Ikke-Likvide Ting 19.794 18.788 4.941 7.707 0.148
Cash Taxes Paid 0 0.002 0.001
Ændringer i Driftskapital 3.738 3.284 4.717 0.625 0.478
Likvider fra Investeringsaktiviteter 58.443 -88.236 -83.164 -0.267 -0.017
Kapitaludgifter -6.526 -1.654 -0.464 -0.267 -0.017
Likvider fra Financieringsaktiviteter 122.908 1.795 360.876 28.395 58.456
Udstedelse (Pensionering) af Aktier, Netto 130.896 1.795 363.85 30 58.456
Udenlandsk Børs Effekter 0.001 -0.005 0.009 -0.014 -0.04
Netto Ændring i Likviditet 65.043 -192.556 224.634 -0.244 41.209
Financiering af Cash-Flow-Ting -7.988 0 -2.974 -1.605 0
Andre Investerings-Cash-Flow-Ting, Total 64.969 -86.582 -82.7
Udstedelse (Pensionering) af Gæld, Netto 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -38.676 -141.947 -107.564 -72.51 -35.373
Cash From Operating Activities -32.993 -116.309 -89.17 -58.452 -30.288
Cash From Operating Activities 0.536 2.106 1.576 1.058 0.518
Non-Cash Items 3.969 19.794 14.89 9.842 4.862
Changes in Working Capital 1.178 3.738 1.928 3.158 -0.295
Cash From Investing Activities 19.517 58.443 102.058 87.96 68.251
Capital Expenditures -0.137 -6.526 -6.244 -6.075 -5.214
Other Investing Cash Flow Items, Total 19.654 64.969 108.302 94.035 73.465
Cash From Financing Activities 17.581 122.908 122.8 0.132 0.019
Financing Cash Flow Items -7.988 -7.853
Issuance (Retirement) of Stock, Net 17.581 130.896 130.653 0.132 0.019
Foreign Exchange Effects -0.005 0.001 -0.007 -0.003 0.003
Net Change in Cash 4.1 65.043 135.681 29.637 37.985
Issuance (Retirement) of Debt, Net
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
Satter Management Co., L.P. Private Equity 13.2922 7056024 0 2023-03-31 MED
Bain Capital Life Sciences Investors, LLC Investment Advisor 10.7413 5701926 815310 2023-05-25 LOW
Adage Capital Management, L.P. Hedge Fund 6.6875 3549975 0 2023-03-31 MED
Redmile Group, LLC Investment Advisor/Hedge Fund 6.5993 3503190 0 2023-03-31 LOW
VR Adviser, LLC Venture Capital 6.066 3220050 0 2023-03-31 MED
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 5.7603 3057800 0 2023-03-31 LOW
Citadel Advisors LLC Hedge Fund 4.5459 2413117 -87190 2023-03-31 HIGH
Eventide Asset Management, LLC Investment Advisor 3.5175 1867250 -1759258 2023-03-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9575 1569971 21100 2023-03-31 LOW
GMT Capital Corp. Hedge Fund 2.6537 1408697 1408697 2023-03-31 LOW
Millennium Management LLC Hedge Fund 2.5702 1364343 837812 2023-03-31 HIGH
Cormorant Asset Management, LP Hedge Fund 2.3548 1250000 1250000 2023-03-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.3222 1232713 0 2023-03-31 LOW
Octagon Capital Advisors LP Hedge Fund 2.2417 1190000 1190000 2023-03-31 MED
Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 2.0552 1090986 -200586 2023-03-31 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 1.9183 1018303 1018303 2023-03-31 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 1.8838 1000000 1000000 2023-03-31 LOW
Soleus Capital Management, L.P. Hedge Fund 1.7244 915400 915400 2023-03-31 HIGH
Novartis AG Corporation 1.7157 910747 -1196497 2021-12-31 LOW
Clarus Ventures, LLC Venture Capital 1.7147 910211 0 2023-03-31 MED

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group

535K+

Handlende

87K+

Månedlkige, aktive klienter

$113M+

Månedlig investeringsvolumen

$64M+

Hævet hver måned

Handelslommeregner

Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

Handelskurtage
0
  • 1:1
Gearing
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long

Annexon, Inc. Company profile

Om Annexon, Inc.

Annexon, Inc. er en biofarmaceutisk virksomhed i den kliniske fase, der udvikler en række behandlinger til patienter med klassiske komplementmedierede sygdomme i kroppen, hjernen og øjet. Selskabets produktkandidat, ANX005, er et fuldlængde monoklonalt antistof, der er formuleret til intravenøs administration ved autoimmune og neurodegenerative sygdomme. Produktkandidaten ANX007 er et antigenbindende fragment (Fab), der er formuleret til intravitreal administration til behandling af neurodegenerative øjensygdomme. Virksomheden er også ved at udvikle ANX009, som er en subkutan formulering af et Fab til behandling af systemiske autoimmune sygdomme. Virksomheden har afsluttet kliniske fase 1b sikkerheds- og doseringsforsøg for ANX005 og ANX007 i patienter med henholdsvis Guillain-Barre syndrom (GBS) og glaukom. Der gennemføres også kliniske forsøg med flere alvorlige autoimmune, neurodegenerative og oftalmiske sygdomme.

Industry: Biopharmaceuticals

1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

BTC/USD

26,937.70 Price
-0.180% 1D Chg, %
Long position, gebyr natten over -0.0616%
Short position, gebyr natten over 0.0137%
Gebyr natten over, tid 21:00 (UTC)
Spænd 60.00

Oil - Crude

71.52 Price
-0.010% 1D Chg, %
Long position, gebyr natten over -0.0179%
Short position, gebyr natten over -0.0040%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.03

XRP/USD

0.53 Price
+1.100% 1D Chg, %
Long position, gebyr natten over -0.0753%
Short position, gebyr natten over 0.0069%
Gebyr natten over, tid 21:00 (UTC)
Spænd 0.00405

US100

14,556.50 Price
-0.070% 1D Chg, %
Long position, gebyr natten over -0.0255%
Short position, gebyr natten over 0.0032%
Gebyr natten over, tid 21:00 (UTC)
Spænd 1.8

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel